Acquisition of further interest in Renalytix AI plc

 26th Apr 2019

Download the full announcement

 

EKF Diagnostics Holdings (AIM: EKF), the AIM quoted point-of-care business, notes the announcement by Renalytix AI plc (AIM: RENX) (“RenalytixAI”), that on 26 April 2019 EKF Diagnostics plc (“EKF”) acquired 100,074 ordinary RenalytixAI shares of £0.0025 each.

Christopher Mills, Julian Baines and Richard Evans (Chairman, CEO and FD/COO respectively of EKF) are each directors of, and directly and indirectly shareholders in, RenalytixAI.

Following the above transaction, which took place at an average price of 123.5973 pence per RenalytixAI share, EKF’s interest in RenalytixAI is now in 2,677,981 Ordinary Shares, representing 4.98% of RenalytixAI’s issued share capital.

Further details of the underlying trades are disclosed in the announcement by RenalytixAI in this regard.

 

Enquiries:

EKF Diagnostics Holdings plc
Christopher Mills, Non-Executive Chairman
Julian Baines, CEO
Richard Evans, Finance Director and COO

www.ekfdiagnostics.com
Tel: 00 44 29 2071 0570
N+1 Singer (Nomad & Broker)

Aubrey Powell / Lauren Kettle / George Tzimas (Corporate Finance)

Tom Salvesen (Corporate Broking)
Tel: 020 7496 3000

Walbrook PR Limited
Paul McManus
Lianne Cawthorne

Tel: 020 7933 8780 or
Mob: 07980 541 893 / 07584 391 303